John W. Kozarich's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 267 Common Stock done at an average price of $161.5 . Disclosure was reported to the exchange on Sept. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 161.51 per share. | 02 Sep 2025 | 267 | 45,722 (0%) | 0% | 161.5 | 43,124 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 162.52 per share. | 02 Sep 2025 | 115 | 45,607 (0%) | 0% | 162.5 | 18,690 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 164.25 per share. | 02 Sep 2025 | 85 | 45,522 (0%) | 0% | 164.2 | 13,961 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 131.88 per share. | 01 Aug 2025 | 467 | 45,989 (0%) | 0% | 131.9 | 61,586 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 10 Jul 2025 | 934 | 46,456 (0%) | 0% | 125 | 116,750 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 47,390 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.30 per share. | 17 Jan 2025 | 2,406 | 46,181 (0%) | 0% | 52.3 | 125,834 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2025 | 2,406 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 43,775 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.35 per share. | 24 Apr 2024 | 2,893 | 42,523 (0%) | 0% | 39.4 | 113,840 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2024 | 2,893 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 39,630 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 77.20 per share. | 16 May 2023 | 4,444 | 38,488 (0%) | 0% | 77.2 | 343,081 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.82 per share. | 08 May 2023 | 6,408 | 48,621 (0%) | 0% | 18.8 | 120,599 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 6,408 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 76.51 per share. | 08 May 2023 | 5,819 | 42,802 (0%) | 0% | 76.5 | 445,218 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 77.10 per share. | 08 May 2023 | 589 | 42,213 (0%) | 0% | 77.1 | 45,410 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 6,623 | 6,623 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 42,213 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 7,335 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.53 per share. | 28 Feb 2022 | 7,335 | 42,117 (0%) | 0% | 12.5 | 91,908 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Sale of securities on an exchange or to another person at price $ 102.62 per share. | 28 Feb 2022 | 908 | 41,209 (0%) | 0% | 102.6 | 93,179 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 34,782 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 4,835 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.12 per share. | 11 May 2021 | 4,835 | 34,543 (0%) | 0% | 10.1 | 48,930 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.56 per share. | 11 May 2021 | 391 | 34,152 (0%) | 0% | 128.6 | 50,267 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.12 per share. | 22 Feb 2021 | 2,500 | 29,708 (0%) | 0% | 10.1 | 25,300 | Common Stock |
| Ligand Pharmaceuticals, In... | John W. Kozarich | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 2,500 | 4,835 | - | - | Non-Qualified Stock Option (right to buy) |